

Special Issue

Modern Approaches in Cardiovascular Disease Therapeutics: From Molecular Genetics to Tissue Engineering

Message from the Guest Editors

Cardiovascular disease is a group of complex disorders which includes peripheral arterial disease, coronary heart disease, cerebrovascular disease and rheumatic heart disease. Each year, more than 800.000 bypass surgeries are performed. Additionally, it is speculated that more than 17 million of people are died due to CAD, which approximately represents the 31% of all deaths, worldwide. The primary cause for the development of CAD is the atherogenesis and the developed atherosclerosis, which induces functional alterations to the vessels of the circulatory system. In this process, individual's genetic background may influence the progression of this disease. Understanding better the individual's genetic alterations, which are specific for the CAD initiation and progression, novel targets for advanced therapeutics may be revealed. Advanced approaches for CAD prevention also involve the use of suitable tissue engineered vascular grafts for bypass surgeries. Modern approaches for CAD will consider individual's own characteristics, promoting in this way advanced personalized therapeutic strategies. We look forward to receiving your valuable contributions.

Guest Editors

Dr. Panagiotis Mallis

Department of Tissue Engineering and Regenerative Medicine of Hellenic Cord Blood Bank, Biomedical Research Foundation Academy of Athens (BRFAA), 11527 Athina, Greece

Dr. Efsthios Michalopoulos

Hellenic Cord Blood Bank, Biomedical Research Foundation Academy of Athens (BRFAA), Athens, Greece

Deadline for manuscript submissions

closed (31 August 2021)



Bioengineering

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 5.3
Indexed in PubMed



mdpi.com/si/53574

Bioengineering
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
bioengineering@mdpi.com

[mdpi.com/journal/
bioengineering](https://mdpi.com/journal/bioengineering)





Bioengineering

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 5.3
Indexed in PubMed



[mdpi.com/journal/
bioengineering](https://mdpi.com/journal/bioengineering)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Bioengineering* (ISSN 2306-5354). *Bioengineering* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. *Bioengineering* provides an advanced forum for the science and technology of bioengineering. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Anthony Guiseppi-Elie

Department of Biomedical Engineering, Texas A&M University, College Station, TX 77843, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPIus / SciFinder, Inspec, and other databases.

Journal Rank:

JCR - Q2 (Engineering, Biomedical) Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.2 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.